Research & Development
CAP issues guideline to improve immunotherapy treatment
The CAP guideline is evidence-based and joins a small number of testing methods based on both the methodology and the status of the biomarker -- i.e., microsatellite testing and deficient mismatch repair process assessment. This stands in contrast to previous guidelines that focused on the cancer type or tumor origin.
August 4, 2022
Lucid launches 3 new test centers
The test centers are staffed with Lucid-employed nurse practitioners who use Lucid's EsoCheck cell collection device to collect surface esophageal cells. Then, the cells undergo Lucid's EsoGuard DNA esophageal test.
March 22, 2022
CAP seeks comment on guidelines for immunotherapy biomarker testing
The guidelines were created jointly by CAP with the following groups:
February 19, 2020
Page 1 of 1